{"url_path":"/register/2026-06-22/2026-12367","section_key":"summary","section_title":"Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams","topic":"register","document":{"doc_type":"Notice","doc_date":"2026-06-22","source_url":"https://www.federalregister.gov/documents/2026/06/22/2026-12367/epizyme-inc-withdrawal-of-approval-of-new-drug-application-for-tazverik-tazemetostat-tablet-200","accession_number":null,"cik":null,"ticker":null,"issuer_name":null,"edgar_url":null,"primary_entity_key":null,"primary_entity_name":"Health and Human Services Department"},"word_count":84,"has_tables":false,"body_markdown":"# Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams\n\n**Type:** Notice\n**Published:** 2026-06-22\n**Citation:** 91 FR 37120\n**Agencies:** Health and Human Services Department, Food and Drug Administration\n**Source:** https://www.federalregister.gov/documents/2026/06/22/2026-12367/epizyme-inc-withdrawal-of-approval-of-new-drug-application-for-tazverik-tazemetostat-tablet-200\n\n## Abstract\nThe Food and Drug Administration (FDA or Agency) is withdrawing approval of new drug application (NDA) for TAZVERIK (tazemetostat) tablet, 200 milligrams (mg), held by Epizyme, Inc., an Ipsen Company (Epizyme), 1 Main St., Cambridge, MA 02142. Epizyme has voluntarily requested withdrawal of its NDA and has waived the expedited withdrawal procedures."}